In vitro study demonstrates dose-dependent upregulation of NFATc1 and c-Src by RANKL in rat marrow cells, indicating a key role in osteoclast differentiation.
This study was designed to determine the effects of receptor activator of nuclear factor κB ligand (RANKL) on the mRNA expression of nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (NFATc1) and c‑Src in rat osteoclast‑like cells. The marrow cells were exposed to macrophage colony-stimulating factor (M‑CSF; 25 ng/ml) and different concentrations of RANKL (0, 50, 75 and 100 ng/ml) for 9 days. The mRNA expression of NFATc1 and c‑Src was determined by polymerase chain reaction. Compared with the M‑CSF (25 ng/ml)+RANKL (0 ng/ml) group, the levels of NFATc1 and c‑Src mRNA expression were significantly increased in the M‑CSF (25 ng/ml)+RANKL (75 and 100 ng/ml) groups (P<0.01, P<0.01, P<0.01 and P<0.01, respectively). Compared with the M‑CSF (25 ng/ml)+RANKL (50 ng/ml) group, the levels of NFATc1 and c‑Src mRNA expression was significantly increased in the M‑CSF (25 ng/ml)+RANKL (75 and 100 ng/ml) groups (P<0.05, P<0.01, P<0.01 and P<0.01, respectively). Compared with M‑CSF (25 ng/ml)+RANKL (75 ng/ml) group, the levels of NFATc1 and c‑Src mRNA expression was significantly increased in the M‑CSF (25 ng/ml)+RANKL (100 ng/ml) group, (P<0.01 and P<0.01, respectively). These data suggest that RANKL could regulate the expression of NFATc1 and c‑Src mRNA in the marrow culture system.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: